Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 317,326 shares of the medical research company's stock after acquiring an additional 17,046 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Edwards Lifesciences worth $23,492,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in EW. Prosperity Consulting Group LLC grew its position in shares of Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares during the period. Abacus Planning Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after buying an additional 140 shares during the period. Moors & Cabot Inc. lifted its position in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of Edwards Lifesciences by 3.1% in the fourth quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after purchasing an additional 156 shares in the last quarter. Finally, Pegasus Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock worth $3,156,000 after purchasing an additional 159 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded up $0.36 during midday trading on Friday, hitting $78.09. 9,048,502 shares of the company's stock traded hands, compared to its average volume of 5,196,842. The firm has a fifty day moving average of $73.35 and a 200 day moving average of $72.50. The stock has a market capitalization of $45.81 billion, a price-to-earnings ratio of 11.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the firm posted $0.66 EPS. The company's revenue was up 6.2% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares of the company's stock, valued at $4,106,859.33. The trade was a 9.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daveen Chopra sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares of the company's stock, valued at $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,442 shares of company stock worth $4,025,799 over the last three months. 0.34% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on EW shares. Citigroup reaffirmed a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Piper Sandler increased their price objective on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Wolfe Research lowered shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Finally, Truist Financial dropped their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.